Search
Neurocrine Biosciences Inc
NBIXAdd to Watchlist
158.290USD
-0.710-0.45%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
15.92BMarket Cap
23.63P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Neurocrine Biosciences Inc is 8.52, ranking 33 out of 157 in the Pharmaceuticals industry. The average price target is 179.00, with a high of 203.00 and a low of 146.00.
Analyst Rating
Based on
31
analysts
Buy
Current Rating
191.545
Target Price
+21.01%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Neurocrine Biosciences Inc
NBIX
31
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Neurocrine Biosciences Inc's expected revenue for the next quarter?
Neurocrine Biosciences Inc's expected revenue is 871.49M.
What is Neurocrine Biosciences Inc's price target?
Analysts forecast that Neurocrine Biosciences Inc's price target is USD 179.00, with the highest forecast at USD 203.00 and the lowest forecast at USD 146.00.
How have Neurocrine Biosciences IncNBIX's recent earnings per share performed?
The market expectation was USD 1.97, while Neurocrine Biosciences IncNBIX's earnings per share (EPS) for the previous quarter was USD 1.54. EPS for the next quarter is expected at USD 1.58.
What is the analyst rating for Neurocrine Biosciences Inc?
Based on the ratings of Neurocrine Biosciences Inc's stock from 31 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
